Skip to main content
Premium Trial:

Request an Annual Quote

Detect Nabs $22.9M BARDA Award to Develop Rapid Molecular COVID-19/Flu Test

NEW YORK – The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority announced last week that it has awarded Connecticut-based diagnostics developer Detect $22.9 million to further develop its COVID-19 and influenza A/B combo test. 

The money will be used to conduct additional studies of the test required by the US Food and Drug Administration to obtain Emergency Use Authorization and eventual 510(k) clearance, BARDA said in a statement. 

The test includes a reusable base station – the Detect Hub – as well as a single-use cartridge and an accompanying mobile application. The isothermal amplification test can be conducted at home with a nasal swab, with results in less than 30 minutes. The cartridge "will allow users to receive independent test results for influenza A, influenza B, SARS-CoV-2, and potential co-infection," BARDA said, noting that the test platform can be quickly reprogrammed to identify new targets and/or pathogenic strains.

The test is expected to be able to detect all known SARS-COV-2 variants, including Omicron.

Detect was founded in early 2020 by sequencing and molecular biology pioneer Jonathan Rothberg.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.